Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib for Prevention of Paclitaxel-Induced Neuropathy in Breast Cancer
NCT04205903Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nilotinib in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Number of Adverse Events up to 6 weeks and Recommended Phase II Dose of Nilotinib in Combination With Paclitaxel up to 6 weeks. Started Dec 2020; status: completed.
02
Drugs
nilotinib
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04205903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205903.